WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018052773) PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/052773    International Application No.:    PCT/US2017/050200
Publication Date: 22.03.2018 International Filing Date: 06.09.2017
IPC:
C07D 401/04 (2006.01), C07D 403/04 (2006.01), A61K 31/4439 (2006.01), A61P 29/00 (2006.01), A61P 35/00 (2006.01), A61P 37/06 (2006.01)
Applicants: BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173 55216 Ingelheim am Rhein (DE)
Inventors: PADYANA, Anil K.; (US).
SPENCER, Elizabeth; (US).
MILLER, Craig Andrew; (US).
LIU, Pingrong; (US).
CUI, Jianwen; (US).
GAO, Donghong Amy; (US).
MCKIBBEN, Bryan Patrick; (US).
RAZAVI, Hossein; (US).
RUPPEL, Sabine; (US)
Agent: BEGAN, Marc; (US).
PATEL, Usha R.; (US).
DATLOW, Philip I.; (US).
KERSHNER, David L.; (US).
DOW, David A.; (US).
MORRISON, Joyce; (US).
GOMBERT, Wendy M.; (US).
ROYAEE, Atabak R.; (US).
LEBEL, Edouard G.; (US).
WITTMAYER, Paula K.; (US)
Priority Data:
62/394,780 15.09.2016 US
Title (EN) PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2
(FR) COMPOSÉS DE PYRIDINE ET DE PYRAZINE EN TANT QU'INHIBITEURS DE RIPK2
Abstract: front page image
(EN)The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes
(FR)La présente invention concerne des composés de formule (I) ou des sels pharmaceutiquement acceptables de ceux-ci, dans laquelle R1, R2, X, Y et HET sont tels que définis dans la description. L'invention concerne également des compositions pharmaceutiques contenant ces composés, des procédés d'utilisation de ces composés pour traiter différents troubles et maladies, ainsi que des procédés de préparation de ces composés et des intermédiaires utilisés dans ces procédés
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)